Taken together, these data support the potential for DNA damage response inhibitors like AZD1390 to selectively enhance the radiation-induced antitumoral immune response and sensitivity to immunotherapy in P53 mutant pancreatic cancer. This evidence concerns the gene TP53 and familial pancreatic carcinoma.